Bioarchitech

Bicester, United Kingdom Founded: 2014 • Age: 12 yrs
Developing novel oncolytic viruses for better tumor targeted efficacy

About Bioarchitech

Bioarchitech is a company based in Bicester (United Kingdom) founded in 2014.. Bioarchitech has raised $358.23 thousand across 5 funding rounds from investors including Oxford Technology. The company has 4 employees as of July 31, 2022. Bioarchitech offers products and services including BA-V151 and BA-R166. Bioarchitech operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.

  • Headquarter Bicester, United Kingdom
  • Employees 4 as on 31 Jul, 2022
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Bioarchitech Ltd
  • Date of Incorporation 23 Jan, 2014
  • Jurisdiction KIDLINGTON, OXFORDSHIRE
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
    $-144.06 K (USD)
    0
    as on Jul 31, 2021
  • EBITDA
  • Total Equity Funding
    $358.23 K (USD)

    in 5 rounds

  • Latest Funding Round
    $117 K (USD), Seed

    Mar 29, 2019

  • Investors
  • Employee Count
    4

    as on Jul 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Bioarchitech

Bioarchitech offers a comprehensive portfolio of products and services, including BA-V151 and BA-R166. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Intravenous viral immunotherapy to kill tumor cells and enhance immunity.

RNA injection inducing immunogenic cell death for early-stage cancers.

Funding Insights of Bioarchitech

Bioarchitech has successfully raised a total of $358.23K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $117 thousand completed in March 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Seed — $117,000
  • First Round

    (13 Aug 2015)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2019 Amount Seed - Bioarchitech Valuation

investors

Oct, 2017 Amount Seed - Bioarchitech Valuation

investors

Jul, 2017 Amount Seed - Bioarchitech Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Bioarchitech

Bioarchitech has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Oxford Technology. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Early-stage micro-VC investments are focused on UK companies.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Bioarchitech

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Bioarchitech

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Bioarchitech Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Bioarchitech

Bioarchitech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
domain founded_year HQ Location
Small molecule therapeutics for cancer treatment are developed.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Therapeutics for cancer and rare diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Bioarchitech

Frequently Asked Questions about Bioarchitech

When was Bioarchitech founded?

Bioarchitech was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Bioarchitech located?

Bioarchitech is headquartered in Bicester, United Kingdom. It is registered at Bicester, Oxfordshire, United Kingdom.

Is Bioarchitech a funded company?

Bioarchitech is a funded company, having raised a total of $358.23K across 5 funding rounds to date. The company's 1st funding round was a Seed of $21.06K, raised on Aug 13, 2015.

How many employees does Bioarchitech have?

As of Jul 31, 2022, the latest employee count at Bioarchitech is 4.

What does Bioarchitech do?

BioArchitech was founded in 2014 in Bicester, United Kingdom, within the biotechnology sector focused on oncology. Technology is being advanced for the production of chimeric oncolytic viruses, which offer improved therapeutic effects at tumor sites and circulation stability to address metastatic spread, a primary factor in cancer-related outcomes. The drug pipeline remains undisclosed as of April 2017.

Who are the top competitors of Bioarchitech?

Bioarchitech's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.

What products or services does Bioarchitech offer?

Bioarchitech offers BA-V151 and BA-R166.

Who are Bioarchitech's investors?

Bioarchitech has 1 investor. Key investors include Oxford Technology.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available